RxDoctor Payments DataLook up a doctor →

Leonard Feiner, MD

Retina Specialist · Union, NJNPI 1841208014

Payments from drug & device makers

$780,912in general payments, 2019–2025

Across 139 payments — averaging $5618.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$663K
  • Apellis Pharmaceuticals, Inc.$59K
  • Regeneron Healthcare Solutions, Inc.$45K
  • Genentech USA, Inc.$7K
  • Otsuka America Pharmaceutical, Inc.$6K
  • BD$900
  • plus $411 from 7 others

What the payments were for

  • Consulting fees$24,22534%
  • Speaking & faculty fees$40,55356%
  • Travel & lodging$5,3167%
  • Food & beverage$2,1893%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$780,912 in reported general payments places this provider in the 95th percentile of 35 retina specialist providers in New Jersey.

See all retina specialist providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,339,742
Medicare patients
714
Services billed
16,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium15$3,097
Prednisolone Acetate62$2,631
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$2,370
Alphagan PBrimonidine Tartrate11$1,892
Latanoprost55$612
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat29$609
Timolol Maleate47$492
Ketorolac Tromethamine30$388
Ofloxacin18$268
Dorzolamide Hcl13$157
Ciprofloxacin Hcl11$109

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P$76$1,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 retina specialist providers in New Jersey.

Other retina specialist in Union

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →